143 related articles for article (PubMed ID: 7752077)
21. Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to ANP in the pregnant rat.
Knight S; Snellen H; Humphreys M; Baylis C
Am J Physiol Renal Physiol; 2007 Feb; 292(2):F655-9. PubMed ID: 17003222
[TBL] [Abstract][Full Text] [Related]
22. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
Chatelain RE; Ghai RD; Trapani AJ; Odorico LM; Dardik BN; De Lombaert S; Lappe RW; Fink CA
J Pharmacol Exp Ther; 1998 Mar; 284(3):974-82. PubMed ID: 9495857
[TBL] [Abstract][Full Text] [Related]
23. Effects of neutral endopeptidase inhibition on the clearance of exogenously administered endothelin in Sprague-Dawley rats.
Asaad MM; Dorso CR; Moreland SM
J Cardiovasc Pharmacol; 1993 Apr; 21(4):633-6. PubMed ID: 7681910
[TBL] [Abstract][Full Text] [Related]
24. Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats.
Kodama K; Adachi H
J Pharmacol Exp Ther; 1999 Aug; 290(2):748-52. PubMed ID: 10411587
[TBL] [Abstract][Full Text] [Related]
25. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
26. Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11.
Trapani AJ; Beil ME; Coté DT; de Lombaert S; Erion MD; Gerlock TE; Ghai RD; Hopkins MF; Peppard JV; Webb RL
J Cardiovasc Pharmacol; 1994 Mar; 23(3):358-64. PubMed ID: 7515977
[TBL] [Abstract][Full Text] [Related]
27. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors.
Hirata Y; Suzuki Y; Suzuki E; Hayakawa H; Kimura K; Goto A; Omata M; Minamino N; Kangawa K; Matsuo H
J Hypertens; 1994 Apr; 12(4):367-74. PubMed ID: 8064160
[TBL] [Abstract][Full Text] [Related]
29. Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats.
Klinger JR; Petit RD; Warburton RR; Wrenn DS; Arnal F; Hill NS
J Appl Physiol (1985); 1993 Oct; 75(4):1615-23. PubMed ID: 8282611
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin-converting enzyme inhibition prevents myocardial infarction-induced increase in renal cortical cGMP and cAMP phosphodiesterase activities.
Clauss F; Charloux A; Piquard F; Doutreleau S; Talha S; Zoll J; Lugnier C; Geny B
Fundam Clin Pharmacol; 2015 Aug; 29(4):352-61. PubMed ID: 25939307
[TBL] [Abstract][Full Text] [Related]
31. Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts.
Redondo J; Bishop JE; Wilkins MR
Br J Pharmacol; 1998 Aug; 124(7):1455-62. PubMed ID: 9723958
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis.
Sansoè G; Aragno M; Mastrocola R; Cutrin JC; Silvano S; Mengozzi G; Smedile A; Rosina F; Danni O; Rizzetto M
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1337-43. PubMed ID: 16449355
[TBL] [Abstract][Full Text] [Related]
33. Blunted effect of ANP on hematocrit and plasma volume in streptozotocin-induced diabetes mellitus in rats.
Valentin JP; Sechi LA; Humphreys MH
Am J Physiol; 1994 Feb; 266(2 Pt 2):R584-91. PubMed ID: 8141419
[TBL] [Abstract][Full Text] [Related]
34. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
[TBL] [Abstract][Full Text] [Related]
35. Chronic administration of phosphodiesterase type 5 inhibitor suppresses renal production of endothelin-1 in dogs with congestive heart failure.
Yamamoto T; Wada A; Ohnishi M; Tsutamoto T; Fujii M; Matsumoto T; Takayama T; Wang X; Kurokawa K; Kinoshita M
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():258S-262S. PubMed ID: 12193099
[TBL] [Abstract][Full Text] [Related]
36. Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation.
Wilkins MR; Settle SL; Needleman P
J Clin Invest; 1990 Apr; 85(4):1274-9. PubMed ID: 2156897
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
Gonzalez W; Beslot F; Laboulandine I; Fournié-Zaluski MC; Roques BP; Michel JB
J Pharmacol Exp Ther; 1996 Aug; 278(2):573-81. PubMed ID: 8768706
[TBL] [Abstract][Full Text] [Related]
38. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor.
Trapani AJ; Smits GJ; McGraw DE; McMahon EG; Blaine EH
J Pharmacol Exp Ther; 1991 Jul; 258(1):269-74. PubMed ID: 1649294
[TBL] [Abstract][Full Text] [Related]
39. Antihypertensive and renal activity of SQ 28,603, an inhibitor of neutral endopeptidase.
Seymour AA; Norman JA; Asaad MM; Fennell SA; Little DK; Kratunis VJ; Rogers WL
J Cardiovasc Pharmacol; 1991 Feb; 17(2):296-304. PubMed ID: 1709235
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.
Seymour AA; Abboa-Offei BE; Smith PL; Mathers PD; Asaad MM; Rogers WL
Clin Exp Pharmacol Physiol; 1995 Jan; 22(1):63-9. PubMed ID: 7768036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
